PEPG PepGen Inc.
Nasdaq · SEC CIK 1835597 · EDGAR
- Bought, last 12 months
- $30.64M 2 purchases by 2 insiders
- Sold, last 12 months
- $59.3K 4 sales by 4 insiders
- Filings on record
- 99 since 2022-05-10, latest 2026-06-22 16:31
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| RA Capital Healthcare Fund LP | Dir, 10% | $30.00M | — |
| Oxford Science Enterprises plc | Former 10% Owner | $640.0K | — |
| McArthur James G | Pres, CEO, Dir | — | $32.9K |
| Donnelly Noel | CFO | — | $13.0K |
| STRECK PAUL | EVP, Head of R, D | — | $11.7K |
| Kasraian Kasra | Chief Technical Off | — | $1,739 |
| Vittiglio Joseph | Chief Business, Legal Off | — | — |
Transactions 59
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-26 16:43 | 2026-05-21 | PEPG | Kasraian Kasra | Chief Technical Off | S - Sale | $1.41 | -1,233 | 50.1K | -2% | -$1,739 | |
| M | 2026-03-06 | 2026-03-04 | PEPG | STRECK PAUL | EVP, Head of R, D | S - Sale | $6.23 | -1,879 | 76.2K | -2% | -$11.7K |
| M | 2026-03-06 | 2026-03-04 | PEPG | McArthur James G | Pres, CEO, Dir | S - Sale | $6.23 | -5,275 | 296.5K | -2% | -$32.9K |
| M | 2026-03-06 | 2026-03-04 | PEPG | Donnelly Noel | CFO | S - Sale | $6.23 | -2,084 | 111.6K | -2% | -$13.0K |
| D | 2026-03-02 | 2026-03-01 | PEPG | Kasraian Kasra | Chief Technical Off | A - Grant | $0.00 | +34.6K | 51.3K | +206% | $0 |
| D | 2026-03-02 | 2026-03-01 | PEPG | Vittiglio Joseph | Chief Business, Legal Off | A - Grant | $0.00 | +30.7K | 65.7K | +88% | $0 |
| D | 2026-03-02 | 2026-03-01 | PEPG | STRECK PAUL | EVP, Head of R, D | A - Grant | $0.00 | +50.3K | 78.1K | +181% | $0 |
| D | 2026-03-02 | 2026-03-01 | PEPG | McArthur James G | Pres, CEO, Dir | A - Grant | $0.00 | +187.7K | 301.6K | +165% | $0 |
| D | 2026-03-02 | 2026-03-01 | PEPG | Donnelly Noel | CFO | A - Grant | $0.00 | +76.8K | 113.7K | +208% | $0 |
| D | 2025-12-10 | 2025-12-08 | PEPG | Vittiglio Joseph | Chief Business, Legal Off | A - Grant | $0.00 | +35.0K | 35.0K | New | $0 |
| 2025-10-01 | 2025-09-30 | PEPG | Oxford Science Enterprises plc | Former 10% Owner | P - Purchase | $3.20 | +200.0K | 4.96M | +4% | +$640.0K | |
| I | 2025-09-30 | 2025-09-26 | PEPG | RA Capital Healthcare Fund LP | Dir, 10% | P - Purchase | $3.20 | +9.38M | 18.55M | +102% | +$30.00M |
| 2025-06-02 | 2025-05-30 | PEPG | STRECK PAUL | EVP, Head of R, D | P - Purchase | $1.24 | +8,375 | 27.8K | +43% | +$10.4K | |
| D | 2025-05-21 | 2025-05-20 | PEPG | Kasraian Kasra | Chief Technical Off | A - Grant | $0.00 | +16.8K | 16.8K | New | $0 |
| 2025-04-22 | 2025-04-17 | PEPG | McArthur James G | Pres, CEO, Dir | P - Purchase | $1.36 | +10.0K | 113.9K | +10% | +$13.6K | |
| 2025-04-09 | 2025-04-08 | PEPG | McArthur James G | Pres, CEO, Dir | P - Purchase | $1.15 | +41.5K | 103.9K | +66% | +$47.7K | |
| D | 2025-03-05 | 2025-03-03 | PEPG | McArthur James G | Pres, CEO, Dir | A - Grant | $0.00 | +60.7K | 62.4K | +3,584% | $0 |
| D | 2025-03-05 | 2025-03-03 | PEPG | STRECK PAUL | EVP, Head of R, D | A - Grant | $0.00 | +19.4K | 19.4K | New | $0 |
| D | 2025-03-05 | 2025-03-03 | PEPG | DeLena Mary Beth | GC | A - Grant | $0.00 | +13.4K | 15.0K | +855% | $0 |
| D | 2025-03-05 | 2025-03-03 | PEPG | Donnelly Noel | CFO | A - Grant | $0.00 | +23.3K | 25.0K | +1,392% | $0 |
| 2025-02-26 | 2025-02-24 | PEPG | DeLena Mary Beth | GC | A - Grant | $0.00 | +3,000 | 3,000 | New | $0 | |
| 2025-02-26 | 2025-02-26 | PEPG | DeLena Mary Beth | GC | S - Sale | $1.68 | -1,432 | 1,568 | -48% | -$2,406 | |
| 2025-02-26 | 2025-02-26 | PEPG | Donnelly Noel | CFO | S - Sale | $1.68 | -1,527 | 1,673 | -48% | -$2,565 | |
| 2025-02-26 | 2025-02-24 | PEPG | Donnelly Noel | CFO | A - Grant | $0.00 | +3,200 | 3,200 | New | $0 | |
| DM | 2024-07-26 | 2024-07-24+ | PEPG | Mellion Michelle L | Chief Medical Off | M - OptEx | $10.21 | +7,772 | 201 | New | +$79.4K |
| DM | 2024-07-26 | 2024-07-24+ | PEPG | Mellion Michelle L | Chief Medical Off | S - Sale+OE | $18.06 | -7,772 | 0 | -100% | -$140.4K |
| D | 2024-07-19 | 2024-07-18 | PEPG | Mellion Michelle L | Chief Medical Off | S - Sale+OE | $18.20 | -12.6K | 0 | -100% | -$229.8K |
| D | 2024-07-19 | 2024-07-18 | PEPG | Mellion Michelle L | Chief Medical Off | M - OptEx | $10.21 | +12.6K | 12.6K | New | +$128.9K |
| DM | 2024-07-16 | 2024-07-12+ | PEPG | Mellion Michelle L | Chief Medical Off | M - OptEx | $10.21 | +9,189 | 3,288 | New | +$93.8K |
| DM | 2024-07-16 | 2024-07-12+ | PEPG | Mellion Michelle L | Chief Medical Off | S - Sale+OE | $18.01 | -9,189 | 0 | -100% | -$165.5K |
| DM | 2024-07-03 | 2024-07-01+ | PEPG | Mellion Michelle L | Chief Medical Off | S - Sale+OE | $18.01 | -912 | 0 | -100% | -$16.4K |
| DM | 2024-07-03 | 2024-07-01+ | PEPG | Mellion Michelle L | Chief Medical Off | M - OptEx | $10.21 | +912 | 875 | New | +$9,312 |
| D | 2024-06-26 | 2024-06-24 | PEPG | Mellion Michelle L | Chief Medical Off | S - Sale+OE | $18.19 | -9,260 | 0 | -100% | -$168.4K |
| D | 2024-06-26 | 2024-06-24 | PEPG | Mellion Michelle L | Chief Medical Off | M - OptEx | $10.21 | +9,260 | 9,260 | New | +$94.5K |
| DM | 2024-06-13 | 2024-06-11+ | PEPG | Mellion Michelle L | Chief Medical Off | S - Sale+OE | $18.05 | -1,586 | 0 | -100% | -$28.6K |
| DM | 2024-06-13 | 2024-06-11+ | PEPG | Mellion Michelle L | Chief Medical Off | M - OptEx | $10.21 | +1,586 | 1,086 | New | +$16.2K |
| DM | 2024-06-07 | 2024-06-05+ | PEPG | Mellion Michelle L | SVP, Clinical Development | M - OptEx | $10.21 | +8,656 | 7,245 | New | +$88.4K |
| DM | 2024-06-07 | 2024-06-05+ | PEPG | Mellion Michelle L | SVP, Clinical Development | S - Sale+OE | $18.08 | -8,656 | 0 | -100% | -$156.5K |
| 2024-05-17 | 2024-05-17 | PEPG | Svenstrup Niels | SVP, Chem. Mfg, Controls | S - Sale | $13.41 | -10.0K | 0 | -100% | -$134.1K | |
| A | 2024-04-09 | 2022-05-10 | PEPG | Oxford Science Enterprises plc | 10% | P - Purchase | $12.00 | +880.0K | 4.76M | +23% | +$10.56M |
| I | 2024-02-13 | 2024-02-09 | PEPG | Kolchinsky Peter | Dir, 10% | P - Purchase | $10.64 | +2.56M | 9.18M | +39% | +$27.21M |
| 2023-12-05 | 2023-11-30 | PEPG | McArthur James G | Pres, CEO, Dir | P - Purchase | $4.17 | +1,694 | 1,694 | New | +$7,064 | |
| D | 2023-06-09 | 2023-06-08 | PEPG | McArthur James G | Pres, CEO, Dir | M - OptEx | $2.71 | +2,381 | 2,381 | New | +$6,453 |
| D | 2023-06-09 | 2023-06-08 | PEPG | McArthur James G | Pres, CEO, Dir | S - Sale+OE | $16.04 | -2,381 | 0 | -100% | -$38.2K |
| DM | 2023-06-08 | 2023-06-06+ | PEPG | McArthur James G | Pres, CEO, Dir | M - OptEx | $2.71 | +26.6K | 8,419 | New | +$72.0K |
| DM | 2023-06-08 | 2023-06-06+ | PEPG | McArthur James G | Pres, CEO, Dir | S - Sale+OE | $16.20 | -26.6K | 0 | -100% | -$430.3K |
| DM | 2023-06-06 | 2023-06-02+ | PEPG | McArthur James G | Pres, CEO, Dir | S - Sale+OE | $16.04 | -2,300 | 0 | -100% | -$36.9K |
| DM | 2023-06-06 | 2023-06-02+ | PEPG | McArthur James G | Pres, CEO, Dir | M - OptEx | $2.71 | +2,300 | 1,800 | New | +$6,233 |
| D | 2023-03-28 | 2023-03-24 | PEPG | Goyal Jaya | EVP, Res, Preclin. Dev | M - OptEx | $10.88 | +392 | 392 | New | +$4,265 |
| D | 2023-03-28 | 2023-03-24 | PEPG | Goyal Jaya | EVP, Res, Preclin. Dev | S - Sale+OE | $20.00 | -392 | 0 | -100% | -$7,840 |
| DM | 2023-02-08 | 2023-02-06+ | PEPG | Goyal Jaya | EVP, Res, Preclin. Dev | M - OptEx | $10.88 | +6,000 | 3,679 | New | +$65.3K |
| DM | 2023-02-08 | 2023-02-06+ | PEPG | Goyal Jaya | EVP, Res, Preclin. Dev | S - Sale+OE | $17.12 | -6,000 | 0 | -100% | -$102.7K |
| 2023-01-19 | 2022-05-06 | PEPG | KEATING LAURIE | Dir | P - Purchase | $12.00 | +4,166 | 4,166 | New | +$50.0K | |
| D | 2022-12-19 | 2022-12-19 | PEPG | Svenstrup Niels | SVP, Chem. Mfg, Controls | M - OptEx | $2.71 | +10.0K | 10.0K | New | +$27.1K |
| DMI | 2022-05-12 | 2022-05-10 | PEPG | Kolchinsky Peter | Dir, 10% | P - Purchase | $12.00 | +3.23M | 1.30M | New | +$38.75M |
| DMI | 2022-05-12 | 2022-05-10 | PEPG | Kolchinsky Peter | Dir, 10% | C - Cnv Deriv | — | +4.90M | 3.64M | New | — |
| DM | 2022-05-10 | 2022-05-10 | PEPG | Oxford Science Enterprises plc | 10% | C - Cnv Deriv | $0.00 | +3.76M | 2.33M | New | $0 |
| DMI | 2022-05-10 | 2022-05-10 | PEPG | Deerfield Private Design Fund V, L.P. | 10%, Possible Member of 10% Group | C - Cnv Deriv | — | +537.0K | 268.5K | New | — |
| DMI | 2022-05-10 | 2022-05-10 | PEPG | Deerfield Private Design Fund V, L.P. | 10%, Possible Member of 10% Group | P - Purchase | $12.00 | +416.7K | 476.8K | +693% | +$5.00M |
Purchase Sale Sale after option exercise All abbreviations